ijms-logo

Journal Browser

Journal Browser

Hormone Secretion and Molecular Alterations in Pancreatic Cell Systems and Metabolic-Related Tissues

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Endocrinology and Metabolism".

Deadline for manuscript submissions: closed (25 January 2024) | Viewed by 14430

Special Issue Editors


E-Mail Website
Guest Editor
Ospedale Garibaldi Nesima, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Catania, Via Palermo 636, Catania, Italy
Interests: diabetes mellitus; pancreatic islets; insulin; glucagon; incretin; GLP-1; apoptosis; hormonal secretion
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Clinical and Experimental Medicine, Internal Medicine, Garibaldi-Nesima Hospital, University of Catania, 95122 Catania, Italy
Interests: intestinal organoids; stem cells; differentiation; diabetes; glucotoxicity; lipotoxicity; molecular biology; cell biology; hormone secretion; pancreatic beta and alpha-cell

E-Mail Website
Guest Editor
Department of Clinical and Experimental Medicine, Internal Medicine, Garibaldi-Nesima Hospital, University of Catania, 95122 Catania, Italy
Interests: NAFLD; liver; diabetes; noncoding RNAs; biomarkers; glucotoxicity; lipotoxicity; molecular biology; cell biology; lipid metabolism
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

The pancreatic islet hormones insulin and glucagon have regulatory roles in the control of metabolic homeostasis. Impaired insulin and glucagon secretion are involved in the pathogenesis of type two diabetes. Metabolic dysfunctions, such as glucotoxicity and lipotoxicity, have a pivotal role in diabetes onset. The main aim of this Special Issue is to evaluate the effect of metabolic perturbation in intracellular signaling of hormones associated with metabolic diseases, cell stress pathways, and hormone production and secretion. We will also focus on studies in which novel molecular pathways will be identified through high-throughput epigenetic and “omics” approaches. This Special Issue will be not limited to pancreatic dysfunction, but will also examine other tissue impairments such as liver (NAFLD/NASH), intestine, and adipose tissue. We are also particularly interested in the use of novel cell biology techniques as 3D organoid culturing in the study of diseases characterized by metabolic and secretory alterations.

Prof. Dr. Salvatore Piro
Dr. Agnese Filippello
Dr. Stefania Di Mauro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hormone secretion
  • metabolic dysfunctions

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

23 pages, 3355 KiB  
Article
Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice
by Ander Vergara, Conxita Jacobs-Cacha, Carmen Llorens-Cebria, Alberto Ortiz, Irene Martinez-Diaz, Nerea Martos, Pamela Dominguez-Báez, Mireia Molina Van den Bosch, Sheila Bermejo, Michael Paul Pieper, Begoña Benito and Maria Jose Soler
Int. J. Mol. Sci. 2022, 23(21), 12823; https://doi.org/10.3390/ijms232112823 - 24 Oct 2022
Cited by 16 | Viewed by 3380
Abstract
Treatments with sodium–glucose 2 cotransporter inhibitors (SGLT2i) or endothelin receptor antagonists (ERA) have shown cardiorenal protective effects. The present study aimed to evaluate the cardiorenal beneficial effects of the combination of SGLT2i and ERA on top of renin–angiotensin system (RAS) blockade. Type 2 [...] Read more.
Treatments with sodium–glucose 2 cotransporter inhibitors (SGLT2i) or endothelin receptor antagonists (ERA) have shown cardiorenal protective effects. The present study aimed to evaluate the cardiorenal beneficial effects of the combination of SGLT2i and ERA on top of renin–angiotensin system (RAS) blockade. Type 2 diabetic mice (db/db) were treated with different combinations of an SGLT2i (empagliflozin), an ERA (atrasentan), and an angiotensin-converting enzyme inhibitor (ramipril) for 8 weeks. Vehicle-treated diabetic mice and non-diabetic mice were included as controls. Weight, blood glucose, blood pressure, and kidney and heart function were monitored during the study. Kidneys and heart were collected for histological examination and to study the intrarenal RAS. Treatment with empagliflozin alone or combined significantly decreased blood glucose compared to vehicle-treated db/db. The dual and triple therapies achieved significantly greater reductions in diastolic blood pressure than ramipril alone. Compared to vehicle-treated db/db, empagliflozin combined with ramipril or in triple therapy significantly prevented GFR increase, but only the triple combination exerted greater protection against podocyte loss. In the heart, empagliflozin alone or combined reduced cardiac isovolumetric relaxation time (IVRT) and left atrium (LA) diameter as compared to vehicle-treated db/db. However, only the triple therapy was able to reduce cardiomyocyte area. Importantly, the add-on triple therapy further enhanced the intrarenal ACE2/Ang(1-7)/Mas protective arm of the RAS. These data suggest that triple therapy with empagliflozin, atrasentan and ramipril show synergistic cardiorenal protective effects in a type 2 diabetic mouse model. Full article
Show Figures

Figure 1

Review

Jump to: Research

8 pages, 1871 KiB  
Review
Metformin: When Should We Fear Lactic Acidosis?
by Stefania Di Mauro, Agnese Filippello, Alessandra Scamporrino, Francesco Purrello, Salvatore Piro and Roberta Malaguarnera
Int. J. Mol. Sci. 2022, 23(15), 8320; https://doi.org/10.3390/ijms23158320 - 28 Jul 2022
Cited by 11 | Viewed by 10334
Abstract
Metformin, a molecule belonging to the biguanide family, represents one of the most commonly prescribed medications for the treatment of diabetes mellitus in the world. Over the sixty years during which it has been used, many benefits have been described, which are not [...] Read more.
Metformin, a molecule belonging to the biguanide family, represents one of the most commonly prescribed medications for the treatment of diabetes mellitus in the world. Over the sixty years during which it has been used, many benefits have been described, which are not limited to the treatment of diabetes mellitus. However, since metformin is similar to other members of the same drug family, there is still much concern regarding the risk of lactic acidosis. This article aims to highlight the correlation between the use of metformin and the onset of renal damage or lactic acidosis. Metformin-associated lactic acidosis exists; however, it is rare. The appropriate use of the drug, under safe conditions, induces benefits without risks. Full article
Show Figures

Figure 1

Back to TopTop